A -- Development and Commercialization of Device For Use in Delivering Agents to Localized Areas of Central Nervous System

The National Institute of Neurological Disease and Stroke (NINDS) seeks a Cooperative Research and Development Agreement (CRADA) Collaborator to work with NINDS in the development and commercialization of device for the delivery of agents using NINDS patented Convection Enhanced Delivery (CED) technology. NINDS has developed a method of delivery of agents into the central nervous system (CNS) by maintaining a pressure gradient during interstitial infusion to enhance the distribution of agent as compared to that which is achievable by diffusion alone. The device will deliver small volumes of agent(s) to large areas at relatively uniform concentrations. Potential Areas of Application - Treatment of inoperable tumors - Treatment of epilepsy - Treatment of Parkinson's disease Main Advantages of Technology/Invention: - Delivery of agents to specific areas of CNS at relatively high concentrations while avoiding systemic toxicity Current State of Development - Numerous pre-clinical studies in animals (including non-human primates) demonstrate the ability of CED to deliver agents within the CNS in a homogeneous, targeted fashion over clinically significant volumes and concentrations. Further R&D Required: - Development of cannula for optimal delivery of agent using CED technology - Development of infusion apparatus for delivery of agents using CED technology Patent Status: - US Patent 5,720,720 for CED method of delivery of agents Submission Dates: - Letter of interest should be received by June 20, 2003. Proposals will be reviewed in order of receipt. Contact Information: - Martha T. Lubet, Ph.D. NINDS Technology Transfer by TTB/ NCI Phone:+1 (555) 000-0000 E-mail contact@example.gov